Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Schneider National heads into its October 29 earnings release with analysts in retreat and the stock down 10% over the past month, creating a straightforward question: have the cuts gone far enough, or is the Street still catching up to the freight reality?
The analyst picture is the defining event of the week. Three firms cut their price targets in three days. JP Morgan's Brian Ossenbeck trimmed to $30 from $35 on Monday, Wells Fargo followed on Tuesday at $35 from $38, and Citigroup moved to $33 from $38 on Wednesday, all while maintaining neutral-equivalent ratings. Not one firm moved to a buy. The consensus target now sits at $36.29, barely 15% above the current price of $31.60, and JP Morgan's $30 target is already at a slight discount to where the stock is trading. Morgan Stanley remains the lone outlier, holding an Overweight with a $45 target set in July. The Street's posture is clear: the rate-cut thesis hasn't translated into a freight recovery, and targets are being walked down ahead of the Q3 print.
Short interest tells a less dramatic story than the price action might suggest. At 6.3% of the free float, short positioning is meaningful but has barely moved this week, up about 0.3% over five days. The borrow market reflects the same lack of urgency. Availability is extremely loose at roughly 12.5 shares available for every one borrowed, well above even the 52-week tightest reading of around 2.4 shares per borrowed share. Cost to borrow is 0.42%, essentially negligible. This is not a stock where short sellers are scrambling for leverage. The bears who are positioned appear comfortable, with no signs of a crowded or contested borrow. Options traders are slightly more cautious than their recent average, with the put/call ratio at 0.096 compared to a 20-day mean of 0.082, roughly one standard deviation above normal, but that is a modest tilt rather than a defensive surge.
The factor scores capture the tension well. Schneider ranks in the 92nd percentile on 12-month forward EPS growth and the 91st on 90-day EPS momentum, suggesting the earnings estimate trajectory has been strong heading in. The EPS surprise rank of 79 and analyst recommendation differential of 93 point to a stock that has habitually beaten lowered bars. Against that, the short score rank of 18 (low, meaning shorts have been light) and an EV/EBIT rank of 11 (expensive on that measure) sketch a name that is priced for recovery without yet delivering it. The EV/EBITDA multiple at 7.0 has contracted 0.25 turns over the past month as the stock has fallen, a modest reset but not yet a compelling value entry by freight-cycle standards. The bear case flagged by the Street, that the company's deliberate shift toward Dedicated contracts caps upside in a spot-market recovery, remains live.
Ownership is unusual for a company of this size. The Schneider family and family-connected trusts retain overwhelming control. Four family members hold Schedule 13D positions on the SEC register covering a combined stake well above 70%. The 13D filing classification means these are declared with activist-eligible intent, though in practice the family's influence is structural rather than agitational. Stakes are as-last-disclosed around the 5% filing threshold, and holders dropping below that level may not file again. BlackRock and Dimensional have been adding modestly in the most recent quarterly periods, while Vanguard's portfolio management arm trimmed by roughly 500,000 shares through June. There is no material institutional re-rating either way.
The last earnings print, in late July, produced a 1.4% gain the following day but gave back essentially all of it over the subsequent five sessions. Q3 results on October 29 will test whether the cost-reduction narrative and Dedicated mix shift are sufficient to meet what has become a very lowered bar from the analyst community.
See the live data behind this article on ORTEX.
Open SNDR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.